Introduction
In the Asian version of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines 1 ) published in 2013, it is stated that "Brachytherapy (low dose rate) is not popular in Asian countries except Japan." In comparison with Western countries, Japan has adopted a very different guiding principle of treatment selection for prostate cancer. For example, endocrine treatment has been indicated as a major treatment option even for early-stage prostate cancer. 2, 3 It is therefore notably important to understand a national trend of Japanese patients who received PBT from the viewpoint of differences in racial and national characteristics.
With the aim of evaluating the safety and efficacy of PBT in Japan, the nationwide J-POPS (NCTC00534196) was initiated in July 2005, and registration continued until December 2010. A total of 6927 patients, approximately 40% of the all cases treated with PBT around the country, were enrolled by the end of 2010. 4 Before and after the publication of a baseline paper of J-POPS, 4 a few analytical studies regarding seed migration, 5 urinary and rectal toxicity profiles, 6 and urethral toxicity 7 were published. The aim of the present study was to evaluate the sexual function of Japanese prostate cancer patients, who did not receive endocrine treatment, before and after PBT based on QOL measures of the EPIC. This is the first report in the world on a multicenter prospective cohort study that has evaluated sexual function after PBT by using the sexual domain questions of the EPIC.
Methods

J-POPS study
We assessed the data obtained from cohort 1 of the J-POPS study. In cohort 1, 42 facilities were registered, and patients were requested to respond to the EPIC questionnaires before PBT and at four subsequent time-points, including 3, 12, 24 and 36 months after the therapy. 8 The described data were transferred from the J-POPS office to the Translational Research Information Center (Kobe, Japan) and statistically analyzed.
Patient selection
We excluded patients who received endocrine treatment within 3 years from PBT, patients with recurrent prostate cancer including those with prostate-specific antigen recurrence, and patients whose EPIC responses were not recorded at the time of enrollment or at the 3-year time-point. As a result, we obtained the final analysis object group of 482 cases (21%; Fig. 1 ).
Japanese-translated version of the EPIC
In consideration of the cultural background of Japanese people, different options were added to the original questions in the sexual domain. Because the questions in the original EPIC were created on the supposition that respondents have any sexual activity, patients who had lost habits of sexual activity or sexual desire before and after therapy could not answer them. In the sexual domain of the Japanese-version EPIC, a new choice ("There was no sexual activity"), counted as 0 points on the given scale, was added to the existing four options in Q18 (How would you describe the usual QUALITY of your erections during the past 4 weeks?). In addition, a new choice ("There was no desire for erection"), counted as 0 points, was added to the existing five options in Q19 (How would you describe the FREQUENCY of your erections during the past 4 weeks?; Table 1 ). It should be noted that when respondents marked the point 0 choice in Q18 or Q19, the data were processed in a similar fashion with the point 1 choice in the English-version EPIC questionnaires (i.e. "None at all" in Q18; "I NEVER had an erection when I wanted one" in Q19).
Analysis items in EPIC questions
We analyzed the chronological changes in overall satisfaction (Q32), as well as sexual summary, sexual function and sexual bother in the sexual domain of the EPIC at the predefined five time-points. All of the five parameters were tabulated according to the EPIC instrument guidelines (https://medic ine.umich.edu/dept/urology/research/epic) scaled from 0 to 100, and lower scores represented worse sexual function, more bother and worse satisfaction.
Evaluation of sexual activity (potency definition)
In evaluating respondents' sexual activity including their potency definition, we evaluated the respondents' sexual In order to analyze the uniqueness among races, we examined the frequencies in which respondents selected choice 0 in Q18 and 19 before PBT.
Use of PDE5i
We created an additional survey retrospectively on the presence or absence of the PDE5i medication history for 3 years after PBT. For patients who took PDE5i during the period, we also investigated the duration of administration and whether the medication (sildenafil, tadalafil or vardenafil) was composed of a single agent or multiple agents.
Statistical analysis
We assessed differences between pretreatment baseline scores and follow-up measurements after PBT in three sexual domains and overall satisfaction. Univariate and multivariate logistic regression analyses were also used to identify a significant set of independent predictors of maintaining potency after PBT with P < 0.05 considered significant. The paired ttest was used to compare the EPIC scores after PBT with the corresponding baseline values. Statistical analyses were carried out by using SAS statistical software (version 9.3; SAS Institute, Cary, NC, USA). All statistical analyses were carried out at the Translational Research Information Center. 4 
Results
Patient characteristics
The median age of the patients was 67.0 years, and patient age was distributed between 50 and 89 years. Only three patients had a history of bladder cancer. The frequency of diabetes patients was 6.2% of all participants (Table 2) . Of the 482 cases, 72 patients (14.9%) received combination therapy of PBT and EBRT. There was no difference in prostate volume between the monotherapy group (PBT) and the PBT + EBRT combination therapy group (P = 0.8946), and prostate D90 values showed a distribution dependent on prescribed doses in both groups (Table 3) . Of the 482 cases, 68 patients (14.1%) had a medication history of PDE5i, of which 44 patients (64.7%) had been administered with two or more agents.
Sexual summary, function, bother and overall satisfaction
In Q18, 222 patients (46.3%) selected "0: There was no sexual activity" before PBT. In Q19, 165 patients (34.6%) selected "0: There was no desire for erection" before PBT. A total of 232 patients (48.2%) circled either of the choices. Meanwhile, 198 cases (41.3%) chose "3: Firm enough for Prostate D90, dose to 90% of the prostate; Prostate V150, % volume of the prostate receiving 150% of the prescription dose; Rectum V100, volume of the rectum in cc receiving 100% of the prescription dose; Urethra D90, dose to 90% of the urethra.
masturbation and foreplay only" or "4: Firm enough for intercourse" in Q18 before PI. The sexual summary, function, bother scores, and overall satisfaction of the treatment at baseline were 46.2 AE 17.0, 30.4 AE 22.1, 82.0 AE 22.9 and 67.1 AE 18.8, respectively. The mean of sexual summary scores at 3, 12, 24, and 36 months after PBT were 38.9, 39.1, 38.6 and 37.2, respectively, which were significantly lower than that at baseline (all P < 0.0001). The mean of sexual function scores at these assessments were 24.0, 24.2, 22.6 and 21.7, respectively, which were also significantly lower compared with that at baseline (all P < 0.0001). Statistically significant differences in the sexual bother scores were also appreciated at these assessments compared with baseline; the mean of sexual bother scores at the assessments were 72.5 (P < 0.0001), 72.7 (P < 0.0293), 74.8 (P < 0.0057) and 72.7 (P < 0.0450), respectively. Significant differences were also found in the overall satisfaction scores at the assessments compared with baseline; the mean overall satisfaction scores at these assessments were 72.6 (P < 0.0027), 76.1 (P < 0.0001), 75.9 (P < 0.0001) and 77.9 (P < 0.0001), respectively. It seems that overall satisfaction scores gradually showed improvement.
Change of sexual activity after PI
In all the 482 patients, the percentages of respondents who selected choice 3 and choice 4 for Q18 before PBT were 9.6% and 31.7%, respectively, whereas these percentages were 12.7% and 16.0%, respectively, 3 years after PBT. The number of patients who selected choice 3 or 4 in Q18 was 198 (41.3%) before PBT; however, the number decreased to 138 (28.7%) 3 years after the therapy (Fig. 2a) .
We also assessed the change of responders who selected choice 3 and choice 4 in the 197 men whose age was ≤65 years before PBT (Fig. 2b) . Of those men, the number of patients who selected choice 3 or 4 in Q18 in 2 years after PBT was 68 (39.3%), and slightly increased up to 88 (44.5%).
Predictive factors for potency retention
We carried out univariate and multivariate analyses to determine background factors predictive of patients who selected choice 3 or 4 in Q18 3 years after PBT. Although PDE5i medication history and radiation dose were not significant, patient age and patient selection of the choice 3 or 4 in Q18 before PBT constituted significant predictive factors (Table 4) .
Discussion
In administering radical treatment for prostate cancer, preservation of male sexual function is one of the important factors for determining therapeutic policies. However, cultural and racial background in relation to the age of onset and the sexual function is not necessarily common throughout the world. The median age of onset in Japanese prostate cancer patients is 72 years, which is older than that in Europe and the USA. 10 The patient median age of patients in the present study was 67 years, and a considerate percentage of the patients fell in the age bracket of >70 years 3 years after PBT. In the present study, the proportion of respondents who answered "There was no sexual activity" or "There was no desire for erection" was 48.1%, which was extremely high compared with previous outcomes in Western countries. The Japanese investigations assessing whether preservation of male sexual function could affect overall QOL in elderly patients receiving PBT might be valuable in consideration of future prevalence of PBT in Asian countries.
Assessments of Japanese male sexual function after PBT have been reported sporadically in recent years. [11] [12] [13] Matsushima et al. reported that male sexual function started to decrease significantly 3 months after PBT, and did not show any upward tendency for the 3-year post-implant period based on the International Index of Erectile Function-15 score. 12 Meanwhile, Nishimura et al. 13 used the Mount Sinai Erectile Function Score 14 for analyses, and reported that the actuarial potency preservation rate fell to 46.2% 6 months after PBT, and then slowly recovered reaching 52.0% 5 years after PBT. Although these two reports used different sexual function measures, they both reported that male sexual function significantly dropped immediately after PBT. However, the previous male sexual function assessments in Japanese men after PBT were all single-center analyses and used an easy-to-use evaluation technique. The present study, in contrast, was expected to enable more accurate evaluation in terms of the determination of actual Japanese male sexual function after PBT for the following reasons: (i) this was a multicenter prospective study; (ii) we excluded factors including endocrine therapy and recurrence, which could affect male sexual function; and (iii) we used the EPIC as an evaluation method.
From the racial viewpoint, we compared the average scores of sexual summary, function and bother items before various treatments (after certain treatments in some cases) among several studies using the EPIC as a sexual function measure (Table 5) . 9, 10, [15] [16] [17] [18] [19] Generally, the patient age before PBT tended to be lower, and thus each of the scores was naturally higher in Europe and the USA studies than Japanese studies, including the present study. Masumori et al. analyzed Japanese erectile status in terms of age ranking. 20 Based on their data, 39% replied severe erectile dysfunction in the 107 men whose age ranged from 60 to 69 years. They concluded that erectile dysfunction and decreased libido were noted by a greater proportion of Japanese than USA men. In our present study, relatively old patient age could affect the results that male sexual function scores in all items of the sexual domain significantly decreased immediately after PBT, and never showed a tendency for recovery. Changes in patients' answers to Q18, which were used to define their sexual function in the present study, showed a similar tendency. Because aging is an important factor for male sexual dysfunction, a future investigation comparing the chronological sexual function between the prostate cancer patients after PBT and the age-matched normal male controls would be intriguing.
In addition to the relatively old age of the study participants, a low administration rate of PDE5i was also deemed to be a key factor in the present results. Pugh et al. encouraged all participants to take PDE5i (tadalafil) after PBT and found that at 24-month follow up, 72% reported erections firm enough for sexual activity and 56% were potent. 9 Similarly, Nishimura et al. 13 reviewed the differences in PDE5i medication rates after PBT among races based on the results by Snyder et al., 21 and pointed out the low PDE5i medication rate as a cause of the significant reduction of Japanese male sexual function after PBT. In our investigation focusing on Q18, the rate of respondents who reported "erections firm enough for sexual activity" 3 years after PBT was merely 28.7%, a 12.6% drop during the post-treatment 3 years in all the 482 cases. However, in a subanalysis of men with relatively young age before PBT (Fig. 2b) , there was a slight improvement of potency between 2 years and 3 years after PI, although the proportion of men who selected choice 4 in the present study 3 years after PBT (27.3%) was strikingly lower than those by Pugh et al. 9 (approximately 50%). A future study is warranted to clarify if continuous administration of PDE5i could contribute to maintaining male sexual function after PBT in patients who have differing levels of male sexual function, and restricted to a young population before PBT and with a desire to maintain the function.
A noteworthy topic of the analyses in the present study was the changes in overall patient satisfaction. In contrast to aggravating male sexual function, overall satisfaction showed continuous improvement. The finding suggests that male sexual function might not be an important factor that determines the overall QOL for a majority of Japanese patients treated with PBT. The same finding was also obtained from an analysis of Japanese men who received PBT in combination with endocrine therapy. In an intermediate risk group, Okihara et al. analyzed changes in subject responses to libido (Q17-1), sexual bother (Q25), and overall satisfaction (Q32) in the EPIC 2 years after PBT in 82 patients who received endocrine therapy for half a year or longer before and after PBT. 22 Consistent with the result of the present present study, they showed that the rate of patients who reported "no sexual activity" or "no desire for erection" before PBT was high (50% and 46%, respectively). In an analysis carried out 2 years after treatment, patients' libido did not improve significantly, while sexual bother worsened slightly, but significantly (average: pretreatment 1.64 vs 2 years after PBT 2.06, P = 0.0051). Similarly with the present study result, overall satisfaction improved significantly. Under the situation where endocrine therapy was carried out continuously, they reported that patient overall satisfaction improved for the following reasons: (i) their average age was 70 years; (ii) their sexual function was already low before PBT; and (iii) cancer control was very favorable in addition to weak points for sexual bother. The present study excluded all patients who received endocrine therapy, but the result showed a similar tendency with the result of the aforementioned paper.
In the present study, significant factors for the preservation of sexual activity were patient age and sexual activity before PBT. Ong et al. 23 used the International Index of Erectile Function-15 score, 12 and analyzed factors predictive of the preservation of male sexual function at 5 years after treatment (the preservation rate 5 years after PBT including mild ED: 59%). Of 366 patients, 45% was administered with PDF5i before and after PBT. For patients who were aged younger than 60 years before PBT, they reported that male sexual function could be preserved in approximately 80% of them 5 years after treatment, and that three significant predictive factors were confirmed: the existence of concomitant disease, biopsy Gleason score and biological effective dose. In comparison with the present investigation, the patient background was quite different in that the age of the patients at the time of treatment was younger and PDE5i medication history was more frequent in their study.
Nishimura et al. analyzed similar predictive factors in Japanese patients, and reported that consistent with the result of the present study, the patient age and the cases with higher Mount Sinai Erectile Function Score scores before PBT constituted significant predictive factors for the preservation of male sexual function. 13 Both the present study and the study by Nishimura et al. reflected actual changes over time in male sexual function of Japanese patients for the past 12 years since PBT was introduced to Japan. 13 
